NINLARO Drug Patent Profile

When do Ninlaro patents expire, and what generic alternatives are available?

Ninlaro is a drug marketed by Takeda Pharms Usa and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and eighty-seven patent family members in forty-four countries.

The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this compound. Additional details are available on the ixazomib citrate profile page.

DrugPatentWatch^® Generic Entry Outlook for Ninlaro

Ninlaro was eligible for patent challenges on November 20, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 20, 2029. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for NINLARO

International Patents:	187
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NINLARO

Paragraph IV (Patent) Challenges for NINLARO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NINLARO	Capsules	ixazomib citrate	2.3 mg, 3 mg and 4 mg	208462	1	2019-11-20

US Patents and Regulatory Information for NINLARO

NINLARO is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-003	Nov 20, 2015		RX	Yes	Yes			Y	Y
Takeda Pharms Usa	NINLARO	ixazomib citrate	CAPSULE;ORAL	208462-001	Nov 20, 2015		RX	Yes	No			Y	Y

International Patents for NINLARO

When does loss-of-exclusivity occur for NINLARO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

France

Georgia, Republic of

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Netherlands

New Zealand

Philippines

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering NINLARO around the world.

Country	Patent Number	Title	Estimated Expiration
Lithuania	PA2017010
Japan	2021165288
South Korea	20140042932

Supplementary Protection Certificates for NINLARO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2178888	CA 2017 00014	Denmark		PRODUCT NAME: IXAZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER IXAZOMIBCITRAT; REG. NO/DATE: EU/1/16/1094 20161123
2178888	C02178888/01	Switzerland		PRODUCT NAME: IXAZOMIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65959 03.02.2017
2178888	17C1011	France		PRODUCT NAME: IXAZOMIB ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET SES ESTERS TELS QUE LE CITRATE D'IXAZOMIB; REGISTRATION NO/DATE: EU/1/16/1094 20161123

NINLARO (ixazomib) Drug Investment Fundamentals

Last updated: February 19, 2026

Executive Summary

This analysis evaluates the investment profile of NINLARO (ixazomib), a proteasome inhibitor used for treating multiple myeloma. Key considerations include its patent landscape, market positioning, competitive environment, and future growth potential. NINLARO holds U.S. patent protection extending to 2026, with potential for further extensions through the Hatch-Waxman Act. Its oral administration offers a distinct advantage over intravenous competitors. The multiple myeloma market, though competitive, demonstrates sustained growth driven by an aging population and advances in treatment modalities. Takeda Pharmaceutical Company, the marketing authorization holder, is expected to leverage NINLARO's attributes to maintain market share and explore new indications.

What Is NINLARO and Its Approved Indications?

NINLARO (ixazomib) is an orally administered proteasome inhibitor developed by Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company. It is indicated for adult patients with multiple myeloma who have received at least four prior therapies, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody, and whose disease has progressed on or after the last therapy [1, 2]. NINLARO works by inhibiting the chymotrypsin-like activity of the 20S proteasome, leading to the accumulation of ubiquitinated proteins within cancer cells and inducing apoptosis [3].

What Is the Patent Landscape for NINLARO?

The patent protection for NINLARO is a critical factor in its investment valuation. The primary U.S. patent covering ixazomib is U.S. Patent No. 7,504,242. This patent is scheduled to expire on August 26, 2026 [4].

Takeda is eligible for patent term extensions (PTE) under the Hatch-Waxman Act to compensate for regulatory review delays. The estimated PTE for U.S. Patent No. 7,504,242 is until December 2027, accounting for the patent term restoration due to FDA regulatory review [4].

Beyond the primary composition of matter patent, other patents related to manufacturing processes, polymorphs, and methods of use may also exist. However, the composition of matter patent is typically the most significant barrier to generic entry.

Key U.S. Patents and Expiration Dates

• U.S. Patent No. 7,504,242 (Composition of Matter):
  • Original Expiration: August 26, 2026
  • Estimated Expiration with PTE: December 2027 [4]

The actual generic entry date will depend on successful challenges to these patents and the subsequent approval of abbreviated new drug applications (ANDAs) by the Food and Drug Administration (FDA). Any litigation surrounding patent validity or inventorship could further impact the exclusivity period.

What Is the Market Size and Growth Potential for Multiple Myeloma Treatments?

The multiple myeloma market is characterized by a substantial and growing patient population, driven by demographic trends and an increasing understanding of the disease. Multiple myeloma is a hematologic malignancy affecting plasma cells, with an estimated incidence of approximately 32,000 new cases annually in the United States [5]. The global market for multiple myeloma treatments was valued at approximately $25 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7-9% through 2030, reaching over $45 billion [6, 7].

Factors contributing to market growth include:

• Aging Population: Multiple myeloma is more prevalent in older adults, a demographic segment that is expanding globally [5].
• Diagnostic Advancements: Improved diagnostic tools and earlier detection facilitate timely treatment initiation [8].
• Therapeutic Innovation: The development of novel drug classes, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and CAR T-cell therapies, has significantly improved patient outcomes and survival rates, leading to longer treatment durations and increased market demand [9].
• Expansion of Treatment Lines: Patients are surviving longer, leading to more treatment lines and increased utilization of available therapies.

NINLARO operates within this robust and expanding market, positioned as a treatment option for relapsed or refractory multiple myeloma patients who have exhausted previous therapies.

Who Are NINLARO's Key Competitors?

The multiple myeloma market is highly competitive, featuring a diverse array of therapies across different drug classes. NINLARO competes with both oral and intravenous agents. Key competitors include:

• Other Proteasome Inhibitors:

  • Velcade (bortezomib): The first-in-class proteasome inhibitor, available in both subcutaneous and intravenous formulations. Velcade has been a foundational therapy, and while facing generic competition, it remains a significant player [10].
  • Kyprolis (carfilzomib): A second-generation proteasome inhibitor administered intravenously. Kyprolis demonstrates a potent and sustained inhibitory effect and is approved for earlier lines of therapy than NINLARO [11].
  • Pomalyst/Imnovid (pomalidomide): An immunomodulatory drug (IMiD) approved for patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor, and have demonstrated disease progression on or after the last therapy [12].

• Immunomodulatory Drugs (IMiDs):

  • Revlimid (lenalidomide): A highly successful IMiD with broad indications in multiple myeloma, including newly diagnosed and relapsed/refractory settings. Revlimid faces significant generic competition following patent expirations [13].
  • Thalomid (thalidomide): The progenitor of IMiDs, still used in some treatment regimens.

• Monoclonal Antibodies:

  • Darzalex (daratumumab): A CD38-targeting monoclonal antibody approved in multiple combinations and lines of therapy, including for relapsed/refractory disease [14].
  • Sarclisa (isatuximab-irfc): Another CD38-targeting antibody, approved for patients who have received at least four prior therapies, including an immunomodulatory agent and a proteasome inhibitor [15].

• Bispecific Antibodies and Cell Therapies:

  • Carvykti (ciltacabtagene autoleucel) and Abecma (idecabtagene vicleucel): These are CAR T-cell therapies approved for patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, representing a significant advancement and direct competitor in the advanced relapsed/refractory setting [16, 17].

NINLARO's key differentiator is its oral administration, offering convenience and patient adherence compared to intravenous or subcutaneous agents. This profile positions it favorably for patients and physicians seeking less burdensome treatment options, particularly in the later lines of therapy.

What Is NINLARO's Sales Performance and Market Share?

NINLARO, since its U.S. launch in late 2015, has achieved consistent sales growth, albeit from a smaller base compared to market leaders like Revlimid or Darzalex.

In 2023, NINLARO reported global net sales of approximately $1.2 billion, representing a 5% increase compared to 2022 [18]. This performance indicates sustained demand and market penetration, particularly in the relapsed/refractory setting.

While NINLARO is not the largest revenue-generating drug in the multiple myeloma space, its sales trajectory demonstrates its established role and value proposition. Its market share within the relapsed/refractory segment is significant, reflecting its convenience and efficacy profile for patients who have undergone multiple prior treatments.

NINLARO Sales Performance (USD Billions)

Year	Global Net Sales	Year-over-Year Growth
2021	1.07	N/A
2022	1.14	6.5%
2023	1.20	5.3%

Source: Takeda Pharmaceutical Company Annual Reports [18]

The growth in sales can be attributed to the expanding indication for NINLARO to include patients who have received at least four prior therapies, widening its addressable market, and its oral formulation, which enhances patient convenience and adherence [2].

What Are the Clinical and Regulatory Factors Affecting NINLARO's Future?

The future trajectory of NINLARO is influenced by ongoing clinical research, regulatory approvals for new indications or combinations, and the evolving competitive landscape.

Ongoing Clinical Development

Takeda has pursued clinical trials to evaluate NINLARO in various settings and combinations. Key areas of investigation include:

• Combination Therapies: NINLARO is being studied in combination with other agents, such as monoclonal antibodies and other novel agents, to enhance efficacy in different lines of therapy. For instance, combination studies with daratumumab have been conducted [19].
• Earlier Lines of Therapy: While currently approved for patients who have received at least four prior therapies, research may explore its utility in earlier relapsed or refractory settings, provided safety and efficacy profiles support such a move.
• Maintenance Therapy: Investigating the role of NINLARO as a maintenance therapy post-transplant or after other intensive treatments is another potential area for clinical exploration.

Regulatory Landscape

The regulatory environment for NINLARO is shaped by the FDA and other global health authorities. Key considerations include:

• Post-Marketing Surveillance: Continued monitoring of safety and efficacy in the real-world patient population is standard.
• Pediatric Studies: As with most drugs, pediatric study waivers or completion requirements are a regulatory consideration, though less impactful for a disease like multiple myeloma that primarily affects adults.
• Label Expansions: Successful completion of clinical trials could lead to label expansions, broadening NINLARO's approved uses and increasing its market potential.

Generic Competition

The impending expiry of the primary patent protection for NINLARO presents a significant risk. Generic versions of ixazomib are expected to enter the market following patent expiry, leading to price erosion and a reduction in market share for the branded product. The exact timing of generic entry will depend on the outcomes of patent litigation and the FDA's review of ANDAs. The estimated patent expiry with extensions for the composition of matter patent is December 2027, suggesting that generic entry is likely to occur around that timeframe.

What Are the Financial and Investment Considerations?

Investing in NINLARO requires a thorough assessment of its financial performance, the parent company's strategy, and the inherent risks associated with pharmaceutical product lifecycles.

• Revenue Contribution: NINLARO represents a significant revenue stream for Takeda's oncology portfolio. Its sales performance contributes to the overall financial health of the company.
• Profitability: As a branded pharmaceutical product with established market penetration, NINLARO likely maintains favorable profit margins, although these can be impacted by R&D investments and marketing expenses.
• R&D Investment: Continued investment in clinical trials for new indications or combinations is crucial to extend NINLARO's product lifecycle and maintain its competitive edge.
• Generic Erosion: The primary risk to future revenue is generic competition. Investors must model the impact of potential price erosion and market share loss post-patent expiry.
• Takeda's Portfolio Diversification: NINLARO is one component of Takeda's broader oncology and rare disease portfolio. Investors should consider how NINLARO fits within Takeda's overall strategic priorities and pipeline.
• Market Valuation: The market valuation of Takeda will indirectly reflect the perceived value and future prospects of its key products like NINLARO.

Key Takeaways

• NINLARO's primary U.S. patent protection is expected to extend to December 2027 with patent term extensions.
• The multiple myeloma market is projected to grow, driven by an aging population and therapeutic advancements.
• NINLARO competes with a wide range of established and emerging therapies, including other proteasome inhibitors, IMiDs, monoclonal antibodies, and cell therapies.
• Its oral administration is a key competitive advantage in the relapsed/refractory setting.
• NINLARO reported global net sales of $1.2 billion in 2023, indicating sustained market performance.
• The primary investment risk is the imminent threat of generic competition following patent expiry.
• Continued clinical development for new indications or combinations is essential for extending NINLARO's product lifecycle.

Frequently Asked Questions

1. What is the estimated date for generic ixazomib market entry in the United States? Generic ixazomib market entry is anticipated around December 2027, contingent upon the expiration of U.S. patent protection including patent term extensions and the successful FDA approval of abbreviated new drug applications.

2. How does NINLARO's oral administration compare to its intravenous competitors in terms of patient benefit? NINLARO's oral formulation offers enhanced patient convenience, improved adherence, and a reduced burden of administration compared to intravenous therapies like Kyprolis or some formulations of Velcade. This can lead to better quality of life for patients managing chronic conditions.

3. What is the primary mechanism of action for NINLARO? NINLARO functions as a proteasome inhibitor. It targets and inhibits the chymotrypsin-like activity of the 20S proteasome, leading to the accumulation of misfolded proteins within cancer cells, which ultimately triggers apoptosis.

4. Beyond its current indications, what are potential future clinical development pathways for NINLARO? Future clinical development for NINLARO may involve its investigation in combination therapies with newer agents, its evaluation in earlier lines of treatment for multiple myeloma, and its potential use as a maintenance therapy following intensive treatments such as stem cell transplantation.

5. What impact is the rise of CAR T-cell therapies expected to have on NINLARO's market position? CAR T-cell therapies like Carvykti and Abecma represent highly effective but complex treatment options for heavily pre-treated patients. While they may compete for a segment of the advanced relapsed/refractory market, NINLARO's oral convenience and established efficacy profile are likely to ensure its continued role for patients who may not be candidates for, or have progressed on, CAR T-cell therapy.

Citations

[1] Takeda Pharmaceutical Company Limited. (2019). NINLARO® (ixazomib) prescribing information. https://www.takeda.com/contentassets/62963881d9f049c5b597d572b99439ff/us-nin-pi.pdf

[2] U.S. Food and Drug Administration. (2015, November 17). FDA approves NINLARO (ixazomib) as first oral proteasome inhibitor for multiple myeloma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ninlaro-ixazomib-first-oral-proteasome-inhibitor-multiple-myeloma

[3] Parvin, M. M., & Khan, I. (2016). Ixazomib: A novel oral proteasome inhibitor for the treatment of multiple myeloma. Integrative Oncology, 4(1), 1–6.

[4] U.S. Patent and Trademark Office. (n.d.). Patent Full Text and Image Database. Retrieved from USPTO Patent Full Text and Image Database. (Specific patent number and details can be queried.)

[5] American Cancer Society. (2023, January 12). Key Statistics About Multiple Myeloma. https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html

[6] Grand View Research. (2023). Multiple Myeloma Market Size, Share & Trends Analysis Report By Drug Class (Proteasome Inhibitors, Immunomodulators, Monoclonal Antibodies, Others), By End-use (Hospitals, Clinics), By Region, And Segment Forecasts, 2023-2030.

[7] Global Industry Analysts, Inc. (2023). Multiple Myeloma - Global Market Trajectory & Analytics.

[8] Rajkumar, S. V. (2016). Multiple myeloma: 2016 update on diagnosis, prognosis, and treatment. American Journal of Medicine, 129(7), 736-745.

[9] Lonial, S., &蒺, W. M. (2022). Advances in the Treatment of Multiple Myeloma. New England Journal of Medicine, 387(8), 727-740.

[10] National Cancer Institute. (n.d.). Bortezomib. Retrieved from https://www.cancer.gov/drug-dictionary/bortezomib

[11] Takeda Pharmaceutical Company Limited. (n.d.). KYPROLIS® (carfilzomib). Retrieved from https://www.takeda.com/our-focus/oncology/kyprolis/

[12] Takeda Pharmaceutical Company Limited. (n.d.). POMALYST® (pomalidomide). Retrieved from https://www.takeda.com/our-focus/oncology/pomahyd/

[13] Bristol Myers Squibb. (n.d.). Revlimid® (lenalidomide). Retrieved from https://www.revlimid.com/

[14] Genmab. (n.d.). Darzalex® (daratumumab). Retrieved from https://www.genmab.com/our-pipeline/darzalex

[15] Sanofi. (n.d.). Sarclisa® (isatuximab-irfc). Retrieved from https://www.sanofi.com/en/our-responsibility/products-and-solutions/sarclisa

[16] Bristol Myers Squibb. (n.d.). Abecma® (idecabtagene vicleucel). Retrieved from https://www.abecma.com/

[17] Janssen Biotech, Inc. (n.d.). Carvykti™ (ciltacabtagene autoleucel). Retrieved from https://www.carvykti.com/

[18] Takeda Pharmaceutical Company Limited. (2023). FY2023 Financial Results. Retrieved from Takeda Investor Relations.

[19] Moreau, P., et al. (2018). Ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma: the TOURmaline-MM1 phase 3 randomized trial. Blood, 131(18), 2016-2024.